Galectin Therapeutics
GALT
GALT
45 hedge funds and large institutions have $8.34M invested in Galectin Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
5% more funds holding
Funds holding: 43 → 45 (+2)
0.94% more ownership
Funds ownership: 9.7% → 10.65% (+0.94%)
Holders
45
Holding in Top 10
–
Calls
$784K
Puts
$272K
Top Buyers
| 1 | +$484K | |
| 2 | +$351K | |
| 3 | +$298K | |
| 4 |
Morgan Stanley
New York
|
+$191K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$175K |
Top Sellers
| 1 | -$31K | |
| 2 | -$13.4K | |
| 3 | -$9.21K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.76K |
| 5 |
Bank of New York Mellon
New York
|
-$2.96K |